{"id":"NCT03523117","sponsor":"American Regent, Inc.","briefTitle":"Multicenter Randomized Active-controlled Study to Investigate Efficacy & Safety of IV FCM in Pediatric Patients With IDA","officialTitle":"A Multicenter, Randomized, Active-Controlled Study to Investigate the Efficacy and Safety of Intravenous Ferric Carboxymaltose in Pediatric Patients With Iron Deficiency Anemia","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2019-01-31","primaryCompletion":"2020-12-22","completion":"2021-01-29","firstPosted":"2018-05-14","resultsPosted":"2022-06-22","lastUpdate":"2022-06-22"},"enrollment":79,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Iron Deficiency Anemia"],"interventions":[{"type":"DRUG","name":"Ferric carboxymaltose","otherNames":["Injectafer","Ferinject"]},{"type":"DRUG","name":"Ferrous Sulfate","otherNames":["oral iron"]}],"arms":[{"label":"Ferric Caroboxymaltose","type":"ACTIVE_COMPARATOR"},{"label":"Oral Ferrous Sulfate","type":"ACTIVE_COMPARATOR"}],"summary":"The primary objective of this study is to demonstrate the efficacy and safety of intravenous ferric carboxymaltose (FCM), compared to oral iron, in pediatric participants who have iron deficiency anemia.","primaryOutcome":{"measure":"Change in Hemoglobin g/dL","timeFrame":"Baseline to day 35","effectByArm":[{"arm":"Ferric Caroboxymaltose","deltaMin":2.22,"sd":null},{"arm":"Oral Ferrous Sulfate","deltaMin":1.92,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"0.3108"}]},"eligibility":{"minAge":"1 Year","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":16,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":40},"commonTop":[]}}